Debbie Wasserman Schultz actually said...
This committee's investigation shines a spotlight on the ways that drug companies use litigation as a key part of their strategic plans to delay generic entry.
Context
Wasserman Schultz discusses drug companies' tactics to maintain high prices through litigation.
09/30/2020